GLP-1 Drugs, Ozempic Misuse, and Eating Disorder Relapse Rapid weight loss, reduced appetite, and feeling full on less food are among the major benefits of the glucagon-like peptide-1 (GLP-1) receptor agonist weight loss drugs semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
B12 injections are generally well-tolerated with mild injection site reactions, though rare hypersensitivity and hypokalaemia can occur, particularly when initiating treatment for severe deficiency
Based on our hypothesis that GLP-1 analogs might be superior to DPP-4 inhibitors for pasireotide-induced hyperglycemia, we switched from alogliptin 25 mg daily to dulaglutide 0.75 mg weekly, while other antidiabetic drugs remained unchanged
If urination has not normalized by week 12, that is a strong signal to discuss it with your healthcare provider and investigate non-tirzepatide causes